Technology
Health
Biotechnology

Eloxx Pharmaceuticals

$9.43
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.34 (-3.48%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell ELOX and other stocks, options, ETFs, and crypto commission-free!

About

Eloxx Pharmaceuticals, Inc. engages in the development of novel ribonucleic acid modulating drug candidates. The firm focuses on the the formulation of medicines to treat rare and ultra-rare premature stop codon diseases. Read More It operates through the United States and Israel geographical segments. Its product includes ELX-02, a small molecule drug designed to restore production of full-length functional proteins which treats cystic fibrosis and cystinosis. The company was founded on December 19, 2017 and is headquartered in Waltham, MA.

Employees
29
Headquarters
Waltham, Massachusetts
Founded
2017
Market Cap
338.97M
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
77.36K
High Today
$10.14
Low Today
$9.09
Open Price
$9.98
Volume
11.92K
52 Week High
$24.60
52 Week Low
$9.09

Collections

Technology
Health
Biotechnology
2018 IPO
US
North America

News

The Motley FoolMay 9

Eloxx Pharmaceuticals, Inc. (ELOX) Q1 2019 Earnings Call Transcript

30
Yahoo FinanceMay 9

Eloxx Pharmaceuticals Reports First Quarter 2019 Financial and Operating Results and Provides Business Update

Positive new preclinical data for Eloxx ERSG molecules presented at the Association for Research in Vision and Ophthalmology (ARVO) 2019 Annual Meeting May 2, 2019 demonstrated: dose dependent restoration of missing protein of Usher Syndrome nonsense mutations, encouraging pharmacokinetics in the retina by intravitreal injection favorable tolerability profile On track to report top line data from Phase 2 clinical trials for ELX-02 in cystic fibrosis and cystinosis in the U.S. and Europe in 2019 Company...

18
Simply Wall StMay 2

Have Insiders Been Buying Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) Shares?

Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! It is not uncommon to see companies perform well in the years after insiders buy shares. Unfortunately, there are also plenty of examples of share prices declining precipitously after insiders have sold shares. So we’ll take a look at whether insiders have been buying or selling shares in Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX). Do Insider Transactions Matter? Most investors know ...

25

Earnings

-$0.40
-$0.35
-$0.31
-$0.26
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
—
Actual
Expected Aug 6, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.